LEP and diabetes mellitus: Leptin treatment has recently been approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the National Institute for Health and Care Excellence (NICE) for the treatment of patients with FPLD2 in whom conventional therapies for diabetes and hypertriglyceridaemia have failed.